A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT06637631
- Phase
- Phase 2
- Recruitment
- Stopped early
- Sponsor
- Sanofi
- Design
- Randomized
- Comparator
- SAR441566 dose 1; SAR441566 dose 2; SAR441566 dose 3; Placebo
- Registry enrollment
- 105
- Endpoint
- Proportion of participants achieving endoscopic response
Study ages: 18 Years to 75 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, France, Georgia, Germany, Hungary, India, Italy, Japan, Mauritius, Netherlands, Poland, Romania, South Korea, Spain, Turkey (Türkiye), United States.
Primary data collection: Jul 30, 2026 (actual). This is not a results-release date.
No results-posting date in this record.
Reported reason for stopping: Business decision.
Evidence 1